Enrollment is critical to a trial, and site performance is a major – if not the most important – driver of that. We’ve always known that our full stack system enables sites to increase efficiency and enhance data quality, but do sites who use CRIO actually enroll more? We now have data to prove that...
Overview With 9 locations in Texas, California and Louisiana, Benchmark Research is the world’s leading vaccine network. Benchmark has performed over 10,000 studies on over 40,000 subjects and has received numerous awards, including being a five-time recipient of the Best Clinical Trial Site/Network award from the World Vaccine Congress. Challenge Historically, Benchmark used paper charts...
Reflections on the Summit The 2021 Global Site Solutions Summit, hosted by the Society for Clinical Research Sites, was an amazing event. The first in-person event that our company has attended in 18 months, the Summit provided an opportunity for CRIO to meet new people and reconnect with clients and friends alike. Post-Pandemic Trends, Here...
Clinical Research IO (CRIO)’s recent site survey showed that most sites have recovered business lost during the pandemic, are adjusting to the decentralized clinical trial model, and have implemented their own software in response. At the beginning of the pandemic, CRIO conducted a survey to look at the impact of coronavirus on research sites. By...
Achieving representative enrollment – meaning diversity in race, age, gender and socioeconomic status – in clinical trials is essential to the development of cutting-edge therapies for the general population. Despite being recognized as a need within the industry, it has proven to be a longstanding challenge. According to the 2019 ‘Drugs Trials Snapshots’ report released...
Disclaimer: The examples noted in the following article are all firsthand accounts of the author, but for the purpose of this article have been combined into a single site visit. The visit depicted below is an aggregate of many sites and studies and is not necessarily an exact representation. The original version was written entirely...
Over the past four months, COVID has led to widespread changes across the clinical research industry, many of which will be carried forwards. 1. Changes in Clinical Trial Protocol & Design According to data collected by the Tufts Center for the Study of Drug Development (CSDD), as of May 20, 2020, more than half of...
Clinical Research IO‘s recent web survey found that COVID-19 is disrupting clinical research sites worldwide. The results are indicative of a significant slowdown in new drug development and long term effects on healthcare in general. 25% of sites have stopped recruiting Of the 75% that are continuing enrollment, about half (37%) are considering halting new...